Daiichi Sankyo Initiates P-II Study of Patritumab Deruxtecan in Patients with EGFR-Mutated NSCLC

 Daiichi Sankyo Initiates P-II Study of Patritumab Deruxtecan in Patients with EGFR-Mutated NSCLC

Daiichi Sankyo Initiates P-II Study of Patritumab Deruxtecan in Patients with EGFR-Mutated NSCLC

Shots:

  • The P-II HERTHENA-Lung01 study involves assessing patritumab deruxtecan in 420 patients in a ratio (1:1) with EGFR-mutated m/ LA NSCLC prior treated with TKI and Pt-based CT. The first patient has been dosed in P-II study
  • The 1EPs of P-II study include ORR and 2EPs include DoR, PFS, DCR, and time to response. Moreover, the level of HER3 protein expression in tumor tissue and its relationship with efficacy will be analyzed along with its PK and immunogenicity
  • Patritumab deruxtecan is an investigational ADC and is comprised of a human anti-HER3 Ab attached to a topoisomerase I inhibitor payload via a stable tetrapeptide-based cleavable linker

Click here ­to­ read full press release/ article | Ref: Businesswire | Image: Medical Dialogues

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post